Product Description: Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer[1][2][3][4][5].
Applications: Metabolism-sugar/lipid metabolism
Formula: C187H291N45O59
Citations: Adv Sci (Weinh). 2025 Aug 28:e17664./bioRxiv. 2023 Jul 19./bioRxiv. 2024 Apr 3./bioRxiv. 2025 April 15./bioRxiv. 2025 Aug 31./bioRxiv. 2025 Jan 10./bioRxiv. 2025 May 14./Cell Prolif. 2025 Aug 27:e70118./Chem Pharm Bull. 2024;72(7):658-663./Diabetes Metab Syndr Obes. 2025 Apr 1:18:969-983./Drug Des Devel Ther. 2024 Nov 30:18:5485-5500./Explor Endocr Metab Dis. 2025 Jun 24;2:101433./Int J Mol Med. 2021 Dec;48(6):219./J Lipid Res. 2024 Dec 24:100736./Metabolism. 2025 Oct 13:156414./Mol Med Rep. 2025 May;31(5):111./NPJ Metab Health Dis. 2025;3(1):10./Patent. US20240366602A1./Res Sq. 2025 May 25./Surgery. 2024 Dec 10:108943./Patent. US12233110./Patent. US12233111./Patent. US12233112.
References: [1]Chang YF, et al. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020 Nov;81:234-239./[2]Liu DX, et al. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022 Jul 13;2022:6813017./[3]Wang C, et al. Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. J Cancer Res Clin Oncol. 2025 Mar 7;151(3):103./[4]Zhang L, et al. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9(1):157-171./[5]Soto-Catalán M, et al. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci. 2024 Mar 4;25(5):2961./[6]Stephen T Buckley, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018 Nov 14;10(467):eaar7047.
CAS Number: 910463-68-2
Molecular Weight: 4113.58
Compound Purity: 99.84
Research Area: Cancer; Metabolic Disease; Neurological Disease
Solubility: DMSO : 5 mg/mL (ultrasonic)/H2O : 3.85 mg/mL (ultrasonic;adjust pH to 1 with 1 M HCl)
Target: Apoptosis;Autophagy;Bcl-2 Family;GLP Receptor;Insulin Receptor;p38 MAPK;α-synuclein
English
Deutsch
